Ochre Bio
UK - OxfordBiotechnology
Focus: Ochre Bio is a UK-based biotechnology company focused on siRNA liver drugs for gene therapy and oncology indications. The company operates as a pre-revenue biotech with a specialized focus on RNA therapeutics targeting hepatic diseases.
Profile data last refreshed 44m ago · AI intelligence enriched 2w ago
Open Jobs
2
Should You Work at Ochre Bio?
AI assessmentOchre Bio is a high-risk, early-stage RNA therapeutics platform play best suited for scientists seeking foundational roles in an emerging modality, not stability or near-term career momentum.
Why Work Here
- Focused expertise in siRNA/RNAi modality at a time of renewed industry momentum in RNA therapeutics — differentiated technical skillset development
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ochre Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.